Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Geron Corporation (GERN : NSDQ)
 
 • Company Description   
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Number of Employees: 229

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.38 Daily Weekly Monthly
20 Day Moving Average: 9,429,135 shares
Shares Outstanding: 636.92 (millions)
Market Capitalization: $878.95 (millions)
Beta: 0.64
52 Week High: $5.06
52 Week Low: $1.17
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.10% -15.33%
12 Week 7.81% -13.33%
Year To Date -61.02% -63.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
919 EAST HILLSDALE BOULEVARD SUITE 250
-
FOSTER CITY,CA 94404
USA
ph: 650-473-7700
fax: 650-473-7750
investor@geron.com http://www.geron.com
 
 • General Corporate Information   
Officers
JOHN A. SCARLETT - President; Chief Executive Officer and Chairman
MICHELLE ROBERTSON - Executive Vice President; Finance; Chief Financi
GAURAV AGGARWAL - Director
DAWN C. BIR - Director
V. BRYAN LAWLIS - Director

Peer Information
Geron Corporation (CORR.)
Geron Corporation (RSPI)
Geron Corporation (CGXP)
Geron Corporation (BGEN)
Geron Corporation (GTBP)
Geron Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 374163103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 636.92
Most Recent Split Date: (:1)
Beta: 0.64
Market Capitalization: $878.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.28
Price/Cash Flow: -
Price / Sales: 7.56
EPS Growth
vs. Year Ago Period: 66.67%
vs. Previous Quarter: 25.00%
Sales Growth
vs. Year Ago Period: 12,927.30%
vs. Previous Quarter: -16.69%
ROE
06/30/25 - -
03/31/25 - -47.86
12/31/24 - -56.48
ROA
06/30/25 - -
03/31/25 - -26.78
12/31/24 - -35.10
Current Ratio
06/30/25 - -
03/31/25 - 7.87
12/31/24 - 5.56
Quick Ratio
06/30/25 - -
03/31/25 - 6.97
12/31/24 - 5.12
Operating Margin
06/30/25 - -
03/31/25 - -118.07
12/31/24 - -224.51
Net Margin
06/30/25 - -
03/31/25 - -119.54
12/31/24 - -226.73
Pre-Tax Margin
06/30/25 - -
03/31/25 - -119.54
12/31/24 - -226.74
Book Value
06/30/25 - -
03/31/25 - 0.42
12/31/24 - 0.46
Inventory Turnover
06/30/25 - -
03/31/25 - 0.08
12/31/24 - 0.08
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.44
12/31/24 - 0.42
Debt-to-Capital
06/30/25 - -
03/31/25 - 30.68
12/31/24 - 29.71
 

Powered by Zacks Investment Research ©